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1. Introduction 
Mass transfer is the net movement of mass from one location to another in response to 
applied driving forces. Mass transfer is used by different scientific disciplines for different 
processes and mechanisms. It is an important phenomena in the pharmaceutical sciences; 
drug synthesis, preformulation investigations, dosage form design and manufacture and 
finally ADME (absorption, distribution, metabolism and excretion) studies. In nature, 
transport occurs in fluids through the combination of advection and diffusion. Diffusion 
occurs as a result of random thermal motion and is mass transfer due to a spatial gradient in 
chemical potential or simply, concentration. However the driving force in convective mass 
transport is the spatial gradient in pressure (Fleisher, 2000). On the other hand, there are 
other variables influencing mass transfer like electrical potential and temperature which are 
important in pharmaceutical sciences. In a complex system mass transfer may be driven by 
multiple driving forces. Mass transfer exists everywhere in nature and also in human body. 
In fact in the body, mass transport occurs across different types of cell membranes under 
different physiological conditions. This chapter is aimed at reviewing transport across 
biological membranes, with an emphasis on intestinal absorption, its model analysis and 
permeability prediction.  
2. Transport across membranes 
Biomembrane or biological membrane is a separating amphipathic layer that acts as a 
barrier within or around a cell. The membrane that retains the cell contents and separates 
the cell from surrounding medium is called plasma membrane. This membrane acts as a 
lipid bilayer permeability barrier in which the hydrocarbon tails are in the centre of the 
bilayer and the electrically charged or polar headgroups are in contact with watery or 
aqueous solutions. There are also protein molecules that are attached to or associated with 
the membrane of a cell. Generally cell membrane proteins are divided into integral 
(intrinsic) and peripheral (extrinsic) classes. Integral membrane proteins containing a 
sequence of hydrophobic group are permanently attached to the membrane while 
peripheral proteins are temporarily attached to the surface of the cell, either to the lipid 
bilayer or to integral proteins. Integral proteins are responsible for identification of the cell 
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for recognition by other cells and immunological behaviour, the initiation of intracellular 
responses to external molecules (like pituitary hormones, prostaglandins, gastric 
peptides,…), moving substances into and out of the cell (like ATPase,…). Concerning mass 
transport across a cell, there are a number of different mechanisms, a molecule may simply 
diffuses across, or be transported by a range of membrane proteins (Washington et al., 2000, 
Lee and Yang, 2001).  
2.1 Passive transport 
Lipophilic drug molecules with low molecular weight are usually passively diffuses across 
the epithelial cells. Diffusion process is driven by random molecular motion and continues 
until a dynamic equilibrium is reached. Passive mass transport is described by Fick,s law 
which states that the rate of diffusion across a membrane  (R) in moles s-1 is proportional to 
the concentration difference on each side of the membrane: 
 R=(Dk/h).A.∆C  (1) 
Where D is the diffusion coefficient of the drug in the membrane, k is the partition 
coefficient of the drug into the membrane, h is the membrane thickness, A is the area of 
membrane over which diffusion is occurring, and ∆C is the difference between 
concentrations on the outside and the inside of the membrane. However it should be noted 
that the concentration of drug in systemic blood circulation is negligible in comparison to 
the drug concentration at the absorption surface and the drug is swept away by the 
circulation. Therefore the driving force for absorption is enhanced by maintaining the large 
concentration gradient throughout the absorption process. The diffusion coefficient of a 
drug is mainly influenced by two important factors, solubility of the drug and its molecular 
weight. For a molecule to diffuse freely in a hydrophobic cell membrane it must be small in 
size, soluble in membrane and also in the aqueous extracellular systems. That means an 
intermediate value of partition coefficient is needed. On the other hand, it is necessary for a 
number of hydrophilic materials, to pass through the cell membranes by membrane 
proteins. These proteins allow their substrates to pass into the cell down a concentration 
gradient, and act like passive but selective pores. For example for glucose diffusion into the 
cell by hexose transporter system, no energy is expended and it occurs down a 
concentration gradient. This process is called non-active facilitated mass transport (Sinko, 
2006, Washington et al., 2000).  
2.2 Active transport 
In the cell membrane there are a group of proteins that actively compile materials in cells 
against a concentration gradient. This process is driven by energy derived from cellular 
metabolism and is defined as primary active trasport. The best-studied systems of this type 
are the ATPase proteins that are particularly important in maintaining concentration 
gradients of small ions in cells. However this process is saturable and in the presence of 
extremely high substrate concentration, the carrier is fully applied and mass transport rate is 
limited. On the other hand cells often have to accumulate other substances like amino acids 
and carbohydrates at high concentrations for which conversion of chemical energy into 
electrostatic potential energy is needed. In this kind of active process, the transport of an ion 
is coupled to that of another molecule, so that moving an ion out of the membrane down the 
concentration gradient, a different molecule moves from lower to higher concentration. 
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Depending on the transport direction this secondary active process is called symport (same 
directions) or antiport (opposite directions). Important examples of this process are 
absoption of glucose and amino acids which are coupled to transporter conformational 
changes driven by transmucosal sodium gradients (Lee and Yang, 2001). 
2.3 Endocytic processes 
All the above-mentioned mass transport mechanisms are only feasible for small molecules, 
less than almost 500 Dalton. Larger objects such as particles and macromolecules are 
absorbed with low efficiency by a completely different mechanism. The process which is 
called cytosis or endocytosis is defied as extending the membrane and enveloping the object 
and can be divided into two types, pinocytosis and phagocytosis. Pinocytosis (cell drinking) 
occurs when dissolved solutes are internalized through binding to non-specific membrane 
receptors (adsorptive pinocytosis) or binding to specific membrane receptors (receptor-
mediated pinocytosis). In some cases, following receptor-mediated pinocytosis the release of 
undegraded uptaken drug into the extracellular space bounded by the basolateral 
membrane is happened. This phenomenon called transytosis, represents an important 
pathway for absorption of proteins and peptides. On the other hand phagocytosis (cell 
eating) occurs when a particulate matter is taken inside a cell. Although phagocytic 
processes are finding applications in oral drug delivery and targeting, it is mainly carried 
out by the specialized cells of the mononuclear phagocyte systems or reticuloendothelial 
system and is not generally relevant to the transport of drugs across absorption barriers (Lee 
and Yang, 2001, Fleisher, 2000, Washington et al., 2000). 
2.4 Pore transport 
The aqueous channels which exist in cell membranes allow very small hydrophilic 
molecules such as urea, water and low molecular weight sugars to be transported into the 
cells. However because of the limited pore size (0.4 nm), this transcellular pathway is of 
minor importance for drug absorption (Fleisher, 2000, Lee and Yang, 2001). 
2.5 Persorption 
As epithelial cells are sloughed off at the tip of the villus, a gap in the membrane is 
temporarily created, allowing entry of materials that are not membrane permeable. This 
process has been termed persorption which is considered as a main way of entering starch 
grains, metallic ion particles and some of polymer particles into the blood. 
3. Intestinal drug absorption 
Interest has grown in using in vitro and in situ methods to predict in vivo absorption 
potential of a drug as early as possible, to determine the mechanism and rate of transport 
across the intestinal mucosa and to alert the formulator about the possible windows of 
absorption and other potential restrictions to the formulation approach. Single-pass 
intestinal perfusion (SPIP) model is one of the mostly used techniques employed in the 
study of intestinal absorption of compounds which provides a prediction of absorbed oral 
dose and intestinal permeability in human. In determination of the permeability of the 
intestinal wall by external perfusion techniques, several models have been proposed (Ho 
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and Higuchi, 1974, Winne, 1978, Winne, 1979, Amidon et al., 1980). In each model, 
assumptions must be made regarding the convection and diffusion conditions in the 
experimental system which affects the interpretation of the resulting permeabilities. In ad-
dition, the appropriateness of the assumptions in the models to the actual experimental 
situation must be determined. Mixing tank (MT) model or well mixed model has been 
previously used to describe the hydrodynamics within the human perfused jejunal segment 
based on a residence time distribution (Lennernas, 1997). This model has also been used in 
vitro to simulate gastrointestinal absorption to assess the effects of drug and system 
parameters on drug absorption (Dressman et al., 1984). However complete radial mixing 
(CRM) model was used to calculate the fraction dose absorbed and intestinal permeability of 
gabapentine in rats (Madan et al., 2005). Moreover these two models (MT and CRM) were 
utilized to develop a theoretical approach for estimation of fraction dose absorbed in human 
based on a macroscopic mass balance approach (MMBA) (Sinko et al., 1991). Although these 
models have been theoretically explained, their comparative suitability to be used for 
experimental data had not been reported.  The comparison of proposed models will help to 
select the best model to establish a strong correlation between rat and human intestinal drug 
absorption potential. In this section three common models for mass transfer in single pass 
perfusion experiments (SPIP) will be compared using the rat data, we obtained in our lab. 
The resulting permeability values differ in each model, and their interpretation rests on the 
validity of the assumptions (valizadeh et al., 2008).  
4. Mass transfer models 
Three models are described that differ in their convection and diffusion assumptions (Fig 1). 
 
 
Fig. 1. Velocity and concentration profiles for the models. The concentration profiles are also 
a function of z except for mixing tank model (Amidon et al., 1980) 
These models are the laminar flow, complete radial mixing (diffusion layer) for convective 
mass transport in a tube and the perfect mixing tank model. It is convenient to begin with 
the solute transport equation in cylindrical coordinates  (Sinko et al., 1991, Elliott et al., 1980, 
Bird et al., 1960):     
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Where, Z* = Z / L,  r* = r / R, z
*υ  = zν  / Vm, Gz = ǑDL/2Q , R = radius of the tube, L = 
length of the tube, Vm = maximum velocity, Q = perfusion flow rate 
This relationship is subject to the first-order boundary condition at the wall:  
 w w
r
C
P C
r *
*
*
1=
∂ = −∂    (3) 
where wP
*  = Pw R/D = the dimensionless wall permeability. 
The main assumptions achieving  Eq. 1 are: (a) the diffusivity and density are constant; (b) 
the solution is dilute so that the solvent convection is unperturbed by the solute; (c) the 
system is at steady state (∂C/∂t = 0); (d) the solvent flows only in the axial (z) direction; (e) 
the tube radius, R, is independent of Gz; and (f) axial diffusion is small compared to axial 
convection (Bird et al., 1960). The boundary condition (Eq. 2) is true for many models having 
a tube wall but does not describe a carrier transport of Michaelis-Menten process at the wall, 
except at low solute concentrations. 
4.1 Complete radial mixing model 
For this model the velocity profile as with the plug flow model is assumed to be constant. In 
addition, the concentration is assumed to be constant radially but not axially. That is, there 
is complete radial but not axial, mixing to give, uniform radial velocity and concentration 
profiles. With these assumptions, the solution is written as: 
 Cm/C0 = exp (-4 effP
*  Gz)  (4) 
where effP
*  replaces wP
*  (Ho and Higuchi, 1974, Winne, 1978, Winne, 1979). Since no aqueous 
resistance is inc1uded in the model directly, the wall resistance is usually augmented with a 
film or diffusion layer resistance. That is, complete radial mixing occurs up to a thin region 
or film adjacent to the membrane. In this model the aqueous (luminal) resistance is confined 
to this region. Hence, the wall permeability includes an aqueous or luminal resistance term 
and can be written as: 
 w aeff
w a
P P
P
P P
* *
*
* *
= +    (5) 
where wP
* is the true wall permeability and aP
* , is the effective aqueous permeability. The 
aqueous permeability often is written as: 
 aP D δ=   (6) 
Or 
 aP R
* δ=   (7) 
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where δ is the film thickness and represents an additional parameter that needs to be 
determined from the data to obtain wP
* . For typical experiments, aP
* or R/δ is an empirical 
parameter, since the assumed hydrodynamic conditions may not be realistic at the low 
Reynolds numbers. The complete radial mixing model also can be derived from a differ-
ential mass balance approach (Ho and Higuchi, 1974) and often is referred to as the 
diffusion layer model. The Calculated effP
* values for tested drugs and the corresponding 
plot are shown in Table 2 and Fig. 2 respectively. 
 
 
Fig. 2. Plot of dimensionless permeability values vs human Peff values in complete radial 
mixing model 
4.2 Laminar flow model 
For flow of a newtonian fluid in a cylindrical tube, the exit concentration of a solute with a 
wall permeability Pw is given by (Amidon et al., 1980): 
 Cm/Co = 
n 1
∞
=∑  Mn exp (-ǃn2 Gz) (8) 
Where, Cm = "cup-mixing" outlet solute concentration from the perfused length of intestine, 
 Co = inlet solute concentration; Gz = ǑDL/2Q;  (9) 
Gz  is Graetz number, the ratio of the mean tube residence time to the time required for 
radial diffusional equilibration. 
D = solute diffusivity in the perfusing fluid 
L = length of the perfused section of intestine 
Q = volumetric flow rate of perfusate = ǑR2(υ) 
R = radius of perfused intestine 
(υ) = mean flow velocity 
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Both the Mn and ǃn in Eq. 7 are functions of wP* , the dimensionless wall permeability, 
 ww
P R
P
D
* =    (10) 
From the form of the solution it appears that Gz is the only independent variable and that 
the solution is an implicit function of wP
* . Since wP
*  (or Pw) is the parameter of interest, Eq. 4 
is not in a convenient form for its determination. 
We now define: 
 
P P
w aq
1 1 1 1 1
* * * * *P P P
eff w aq
= + = +
° °
  (11) 
 
m
eff
C C
P
Gz
0 exp*
ln[( )]
4
= −   (12) 
 maq
C C
P
Gz
* 0 0ln[( )]
4
° = −   (13) 
 om n n
n
C C M Gz
5
2
0 0
1
[( )] exp( )β°
=
= −∑  (14) 
where the superscript o denotes the sink condition (Graetz solution), the superscript * 
denotes dimensionless quantities [Eq. 8] and subscripts exp stands for experimental 
condition. The wall permeability is determined in the following manner: First the aqP
*° is 
calculated using Eqs. 9 , 11, 14 and Table 1. 
 
nM
°  nβ°  (n) 
0.81905 2.7043 1 
0.09752 6.6790 2 
0.03250 10.6734 3 
0.01544 14.6711 4 
0.00878 18.6699 5 
Table 1. Coefficients, nM
° and exponents, nβ° for the Graetz solution, equation (12), (sink 
conditions) (Elliott et al., 1980)  
Then the effP
* is calculated from the experimental results using Eq. 8 and 11 at the third step 
the value of wP
*° is found out  from Eq. 10 and finally the value of wP
*°  is multiplied by the 
correction factor in Fig 3 to obtain wP
* .  
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Fig. 3. Correction factor to obtain exact wall permeability ( wP
* ) given the estimated wall 
Permeability ( wP
*° ) and value of Gz. (Elliott et al., 1980) 
All calculations were performed for our data in SPIP model. The Gz values were calculated 
based on equation 8, using the compound diffusivity, length of intestine and flow rate of 
perfusion which are shown in Table 2. The average value of Gz was found to be 3.34×10-2 (± 
8.6×10-3). It seems that there are limitations for the use of laminar flow model in determination 
of the dimensionless wall permeability of highly permeable drugs. For instance a negative 
value of ibuprofen dimensionless wall permeability was obtained based on laminar flow 
model because of the high P*eff value of ibuprofen in comparison with its calculated P*aq sink 
value and as a result the drug was excluded from correlation plot. Table 2 also represents the 
obtained dimensionless rat gut wall permeabilities ( wP
* ) for tested compounds. The plot of 
wP
* versus the observed human intestinal permeability values is shown in Fig. 4.  
 
 
Fig. 4. Plot of dimensionless rat gut wall permeability values vs human Peff values in 
laminar flow model 
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4.3 Mixing tank model 
This model takes the next step and assumes that both radial and axial mixing are complete. 
The aqueous resistance again is believed to be confined to a region (film) next to the 
membrane where only molecular diffusion occurs, and the rest of the contents are well 
mixed (perfect mixer). This model is described most easily by a mass balance on the system: 
(mass/time)inlet - (mass/time)outlet = (mass/time)absorbed or: 
 QC0 – QCm= (2ǑRL)( effP' )Cm (15) 
where 2ǑRL is the area of the mass transfer surface (cylinder) of length L and radius R, effP' is 
the permeabilily or mass transfer coefficient of the surface, and Cm is the concentration in 
the tube (which is constant and equal to the outlet concentration by the perfect mixing 
assumption). From Eq. 15 it is obtained: 
 m eff
m
C C RL
P
C Q
'0 2π− =   (16) 
 m effC C P Gz
'*
0 1 4= +   (17) 
As with the complete radial mixing model, P*eff contains additional parameter aP R
* δ ′′ =  
that must be estimated from the data, The aP
*′  and effP *′ values for the mixing tank model 
differ from those for the complete radial mixing model by nature of the different 
hydrodynamic assumptions (Amidon et al., 1980). While this model is not appropriate to 
most perfusion experiments, it is useful to compare its ability for correlation of mass transfer 
data with other models. As a matter of fact the effP
* for our data was calculated on the basis 
of assumptions of mixing tank model. The data and representative plot for this model are 
shown in Table 2 and Fig. 5 respectively (Valizadeh et al. 2008). 
 
 
Fig. 5. Plot of dimensionless permeability values vs human Peff values in mixing tank model 
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Diffusivitya 
(×10-6 m2/sec) 
Rat
no.
Graetz no.eff
P* (±SD)
(CRM) 
effP
* (±SD) 
(MT) 
wallP
* (±SD) 
(LF) 
Compound 
13.53E-02
23.46E-02 7.70 
32.59E-02
0.37±0.000.38±0.00 0.41± 0.00 Atenolol 
13.32E-02
24.68E-02 8.70 
33.98E-02
0.99±0.021.06±0.03 1.46± 0.07 Cimetidine 
12.99E-02
23.16E-02 7.40 
32.16E-02
0.55±0.020.57±0.25 0.67± 0.32 Ranitidine 
15.34E-02
23.56E-02 9.92 
34.45E-02
1.07±0.041.18±0.06 1.65± 0.13 Antipyrine 
12.01E-02
21.39E-02 4.98 
31.68E-02
1.21± 0.561.28±0.62 1.94± 1.35 Metoprolol 
12.84E-02
23.56E-02 7.92 
32.74E-02
1.80±0.922.09±1.18 11.70 ± 14.4Piroxicam 
13.46E-02
23.98E-02 7.70 
35.19E-02
1.32±0.481.50±0.61 2.72± 1.8 Propranolol 
13.71E-02
23.94E-02 8.70 
33.47E-02
1.29±0.121.42±0.14 2.17± 0.35 Carbamazepine 
12.92E-02
22.36E-02 8.22 
32.58E-02
0.72±0.440.76±0.47 0.98± 0.69 Furosemide 
14.07E-02
24.24E-02
33.82E-02
9.26 
44.15E-02
0.39±0.210.41±0.22 0.46± 0.26 Hydrochlorothiazide
13.82E-02
22.49E-02 7.40 
32.76E-02
4.85±0.546.54±0.53 ------- Ibuprofen 
13.40E-02
23.02E-02
34.53E-02
8.42 
42.72E-02
2.06±0.402.38±0.52 7.07±3.97 Ketoprofen 
13.26E-02
23.26E-02
32.92E-02
8.55 
42.96E-02
2.43±0.412.85±0.55 16.59± 15.8Naproxen 
a Diffusivities were calculated using 2D structure of compounds applying he method proposed by 
Heyduk et al (Hayduk and Laudie, 1974)  
Table 2. Dimensionless permeabilities determined based on three mass transfer models 
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The calculated dimensionless wall permeability values were in the range of 0.37 – 4.85, 0.38-
6.54 and 0.41-16.59 for complete radial mixing, mixing tank and laminar flow models 
respectively. It is clear that drugs with different physicochemical properties belonging to all 
four biopharmaceutical classes were enrolled in the study. Atenolol a class III drug (high 
soluble-low permeable) showed lowest effective permeability value in all three investigated 
models. It is also shown that there is only a small difference in the calculated atenolol 
permeability coefficients in three models. However this variation becomes more salient for 
high permeable drugs; i.e. class I (high soluble-high permeable) and class II (low soluble-
high permeable) drugs especially in term of permeability in laminar flow model. For 
instance the observed mean permeability values for naproxen, a class II drug, are 2.43, 2.85 
and 16.59 in CRM, MT and LF models respectively. Therefore it seems that in comparison to 
other model laminar flow model provides larger values for highly permeable drugs in 
comparison to the other models. However the ranking order for intestinal absorption of 
tested drugs is almost the same in other evaluated models. In addition it seems that it would 
be possible to classify drugs correctly by the resulting values. Fig. 2, 4 and 5 demonstrate the 
obtained correlations for investigated models. It is seen that the plots of rat permeability 
versus human Peff values, present rather high linear correlations with intercepts not 
markedly different from zero (R2= 0.81, P <0.0001 for MT, R2= 0.75, P =0.0005 for LF, R2= 
0.84, P <0.0001 for CRM). The permeabilities differ for the various models. The 
permeabilities resulting from application of the other models can be interpreted if it is 
assumed that the laminar flow permeability measures the wall permeability. The 
permeability values for the complete radial mixing model are lower than the laminar flow 
model since this model assumes radial mixing, which leads to lower estimated luminal 
(aqueous) resistance values and a higher estimated membrane resistance (lower 
permeability value). However, the usual interpretation of the complete radial mixing model 
recognizes that the permeability value includes an aqueous resistance. While the 
permeabilities in mixing tank model, which takes the final step in assuming both radial and 
axial mixing, were expected to be the lowest among all models, they were in the range 
between permeabilities in complete radial mixing and dimensionless wall permeabilities. 
Although theoretically laminar flow model has been established to a reasonable 
approximation in external perfusion studies, based on the results of correlations of this 
study, it seems the hydrodynamics in normal physiological situation clearly are more 
complex and need more investigation to choose from proposed models. Therefore it is 
concluded that all investigated models work relatively well for our data despite 
fundamentally different assumptions. The wall permeabilities fall in the order laminar flow 
> mixing tank > complete radial mixing. Based on obtained correlations it is also concluded 
that although laminar flow model provides the most direct measure of the intrinsic wall 
permeability, it has limitations for highly permeable drugs such as ibuprofen and the 
normal physiological hydrodynamics is more complex and finding real hydrodynamics 
require further investigations. 
5. Prediction of human intestinal permeability using SPIP technique 
Previous studies have shown that the extent of absorption in humans can be predicted from 
single-pass intestinal perfusion technique in rat (Salphati et al., 2001, Fagerholm et al., 1996), 
however, in this section (Zakeri-Milani et al., 2007) we compare the quantitative differences 
between permeabilities in human and rat models directly using a larger number of model 
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drugs with a broad range of physicochemical properties for both high and low permeability 
classes of drugs. In fact more poorly absorbed drugs (cimetidine and ranitidine) have been 
included in the present work and therefore it is likely that the obtained equations will give a 
more reliable prediction of the human intestinal permeability and fraction of dose absorbed 
than previously reported equations. Single-pass intestinal perfusion studies in rats were 
performed using established methods adapted from the literature. Briefly, rats were 
anaesthetized using an intra peritoneal injection of pentobarbital (60 mg/kg) and placed on 
a heated pad to keep normal body temperature. The small intestine was surgically exposed 
and 10 cm of jejunum was ligated for perfusion and cannulated with plastic tubing. The 
cannulated segment rinsed with saline (37oC) and attached to the perfusion assembly which 
consisted of a syringe pump and a 60 ml syringe was connected to it. Care was taken to 
handle the small intestine gently and to minimize the surgery in order to maintain an intact 
blood supply. Blank perfusion buffer was infused for 10 min by a syringe pump followed by 
perfusion of compounds at a flow rate of 0.2 ml/min for 90 min. The perfusate was collected 
every 10 min in microtubes. The length of segment was measured following the last 
collection and finally the animal was euthanitized with a cardiac injection of saturated 
solution of KCl. Samples were frozen immediately and stored at -20oC until analysis. 
Effective permeability (Peff ) (or better named practical permeability, since the effective area 
of segment is not considered in the calculation) was calculated using following equation 
(Eq.18) according to the parallel tube mode: 
 Peff= -Q ln(Cout/Cin)/2Ǒrl  ( 18) 
In which Cin is the inlet concentration and Cout is the outlet concentration of compound 
which is corrected for volume change in segment using phenol red concentration in inlet 
and outlet tubing. Q is the flow rate (0.2 ml/min), r is the rat intestinal radius (0.18 cm) and l 
is the length of the segment. It has been demonstrated that in humans at a Qin of 2-3 
ml/min, Peff is membrane-controlled. In the rat model the Qin is scaled to 0.2 ml/min, since 
the radius of the rat intestine is about 10 times less than that of human. In 1998 Chiou and 
Barve (Chiou and Barve, 1998) reported a great similarity in oral absorption (Fa) between rat 
and human; however they have used an in vivo method, quite different from in situ 
techniques, that can give an idea of the absorption from the entire GI tract, therefore the 
significance of rat jejunal permeability values for predicting the human Fa has not been 
tested in that report. In the present study the obtained Peff values ranged between 2 ×10-4 
cm/sec to 1. 6 ×10-5 cm/sec and showed a high correlation (R2=0.93, P<0.0001) with human 
Peff data for passively absorbed compounds (Fig 6) confirming the validity of our procedure. 
This correlation was weakened when the actively transported compounds (cephalexin and ǂ 
methyl dopa) were added to the regression (R2=0.87, P<0.0001).  
The plot of predicted vs observed human Peff values presents a high linear correlation with 
intercept not markedly different from zero (R2= 0.93, P <0.0001) (Zakeri-Milani et al., 2007). 
According to previously reported equations by Salphati et al (Salphati et al., 2001) in the 
ileum and Fagerholm et al (Fagerholm et al., 1996) in the jejunal segment, the slopes for the 
same correlation between two models were 6.2 and 3.6 respectively. However based on our 
results for larger set of compounds including more low-permeable drugs the rat Peff values 
were on average 11 times lower than those in human. The species differences and the 
differences in effective absorptive area might be the reasons for the lower permeability 
values in the rat model. In addition, any changes in the intestinal barrier function during the 
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surgery might be a main reason for obtaining different results in literature concerning 
intestinal permeability of drugs. A strong correlation was observed between rat 
permeability data and fraction of oral dose absorbed in human fitting to chapman type 
equation; Fa (human) = 1- e -38450Peff (rat) (R2= 0.91, P<0.0001) (Fig. 7).  
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Fig. 6. Plot of Peff rat vs Peff human 
 
 
Fig. 7. Plot of rat Peff vs human Fa 
The same fitting using human intestinal permeability gives a lower correlation coefficient. 
The comparison of rat Peff and intestinal absorption in man (Fa) showed that rat Peff values 
greater than 5.9×10-5 cm/sec corresponds to Fa ≈ 1 while rat Peff values smaller than 3.32×10-5 
cm/sec corresponds to Fa values lower than 0.6. Corresponding estimates in human are > 
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0.2×10-4 cm/sec and <0.03×10-4 cm/sec, respectively. Moreover the predicted and observed 
human Fa (%) are linearly correlated (R2 = 0.92, P <0.0001). The rank order for Peff values in 
rat was compared with those of human Peff and Fa (Zakeri-Milani et al., 2007). The spearman 
rank correlation coefficients (rs) were found to be 0.96 and 0.91 respectively. Based on the 
obtained results, it is concluded that in situ perfusion technique in rat could be used as a 
reliable technique to predict human gastrointestinal absorption extent following oral 
administration of a drug. However, to render our observation more reliable, it seems that 
using larger number of compounds belonging to all four biopharmaceutical classes, i.e., 
different solubility and permeability properties (Lobenberg and Amidon, 2000) especially 
drugs with low permeability must be tested.  
6. Biopharmaceutics classification system using rat Peff as a surrogate for 
human Peff 
In 1995 Amidon et al. devised a biopharmacetics classification system (BCS) to classify drugs 
based on their aqueous solubility and intestinal permeability, two fundamental properties 
governing drug absorption (Amidon et al., 1995). This system divides active moieties into 
four classes: class I (high permeability, high solubility), class II (high permeability, low 
solubility), class III (low permeability, high solubility) and class IV (low permeability, low 
solubility).  For highly permeable drugs the extent of fraction dose absorbed in human is 
considered to be more than 90% as defined by US Food and Drug Administration (FDA) 
(Lennernas and Abrahamsson, 2005, Zakeri-Milani et al., 2009a). The classification of drug 
solubility is based on the dimensionless dose number (D0) which is the ratio of drug 
concentration in the administered volume (250 ml) to the saturation solubility of the drug in 
water. If a drug has dose/solubility ratio less than 250 ml over the pH range from 1 to 7.5 it 
is classified as highly soluble drug compound (Kasim et al., 2004). BCS classification can 
help pharmaceutical companies to save a significant amount in development time and 
reduce costs. This classification provides a regulatory tool to substitute in vivo 
bioequivalence (BE) studies by in vitro dissolution tests.  In fact for immediate-release (IR) 
solid oral dosage forms containing rapidly dissolving and easily permeating active 
ingredients bioequivalence studies may not be required because they act like a solution after 
oral administration. Therefore dissolution rate has a negligible impact on bioavailability of 
highly soluble and highly permeable (BCS Class I) drugs. As a result, various regulatory 
agencies including the United States Food and Drug Administration (FDA) now allow 
bioequivalence of formulations of BCS Class I drugs to be demonstrated by in vitro 
dissolution (often called a biowaiver) (Takagi et al., 2006) . Waivers for class III drugs have 
also been recommended (Blume and Schug, 1999, Yu et al., 2002) . Moreover BCS provides 
distinct rules for determining the rate-limiting factor in the gastrointestinal drug absorption 
process. As a result it could be helpful in the selection of candidate drugs for full 
development, prediction and clarification of food interactions, choice of formulation 
principle and the possibility of in vitro-in vivo correlation in the dissolution testing of solid 
formulations (Lennernas and Abrahamsson, 2005, Fleisher et al., 1999). Although 
permeability classification of drugs would be ideally based on human jejunal permeability 
data, such information is available for only a small number of drugs. Therefore in this 
section a new classification is presented which is based on a correlation between rat and 
human intestinal permeability values. However first the calculation of used parameters is 
explained.  
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7. Dose number calculation 
Dose number is a criterion for solubility (Do) which is defined as the ratio of dose 
concentration to drug solubility. It is calculated as follows: 
 oo
s
M V
D
C
/=   (19)  
Where (Cs) is the solubility, (M) is the maximum dose strength, and (Vo) is the volume of 
water taken with the dose (generally set to be 250 mL). The values of solubility and 
maximum dose strength of tested compounds are listed in table 3 . Dose number would be 
as unity (Do = 1), when the maximum dose strength is soluble in 250 ml of water and the 
drug is in solution form throughout the GI tract. This criterion is extended to 0.5 for 
borderline classification, considering the average volume of fluid (500 ml) under fed 
conditions (Zakeri-Milani et al., 2009b).  
8. Dissolution number calculation 
Dissolution number refers to the time required for drug dissolution which is the ratio of the 
intestinal residence time to the dissolution time, which includes solubility (Cs), diffusivity 
(D), density (ǒ), initial particle radius (r0) of a compound and the intestinal transit time (Tsi) 
(Zakeri-Milani et al., 2009b, Varma et al., 2004). 
 
s si
si
diss
TD C
Dn T
r T20
3
ρ
⎛ ⎞⎛ ⎞= =⎜ ⎟⎜ ⎟⎝ ⎠⎝ ⎠
   (20) 
where ǒ and Tsi are generally considered to be 1200 mg/cm3 and 199 min respectively. 
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s
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T
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0
3
ρ=  (21) 
9. Absorption number calculation 
This is the ratio of permeability (Peff) and the gut radius (R) times the residence time in the 
small intestine which can be written as ratio of residence time and absorption time (Zakeri-
Milani et al., 2009b, Varma et al., 2004). 
  
eff si
si
abs
TP
An T
R T
*= =   (22)  
For calculation the R value of 1.7 cm and the predicted human Peff (based on rat Peff) were 
used. 
10. Absorption time calculation 
This parameter is proportional to Peff through the following equation (Zakeri-Milani et al., 
2009b, Varma et al., 2004). 
www.intechopen.com
 Mass Transfer in Multiphase Systems and its Applications 
 
608 
 abs
eff
R
T
P
=  (23) 
11. Absorbable dose calculation 
Absorbable dose is the amount of drug that can be absorbed during the period of transit 
time, when the solution contacting the effective intestinal surface area for absorption is 
saturated with the drug (Zakeri-Milani et al., 2009b, Varma et al., 2004). 
 abs eff s siD P C A T= < >   (24) 
In this equation A is the effective intestinal surface area for absorption. If the small intestine 
is assumed to be a cylindrical tube with a radius of about 1.5 cm and length of 350 cm, the 
available surface area and volume are 3297 cm2 and 2473 ml, respectively. In reality, the 
actual volume is around 600 ml and the effective intestinal surface area is then estimated to 
be about 800 cm2 assuming the same ratio. Drugs were classified to the BCS on the basis of 
dose number (Do) and rat jejunal permeability values, which are taken as indicative of 
fundamental properties of drug absorption, solubility and permeability. On the basis of the 
relationship between human and rat intestinal permeability (Zakeri-Milani et al., 2009a, 
Zakeri-Milani et al., 2007) , rat Peff values greater than 5.09×10-5 cm/sec corresponds to Fa > 
85 % while Peff values smaller than 4.2×10-5 cm/sec corresponds to Fa values lower than 80 
%. Therefore, as it can be seen in Fig 8 a cutoff for highly permeable drugs, Peff rat = 5.09×10-5 
cm/sec with a border line cutoff of 4.2×10-5 cm/sec can be set. Drugs with permeability in 
the range of 4.2-5.09e-5 cm/sec were considered as borderline drugs. The intersections of 
dashed lines drawn at the cutoff points for permeability and dose/solubility ratio divide the 
plane in Fig. 8 into four explicitly defined drug categories (I – IV) and a region of borderline.  
 
 
Fig. 8. Plot of Dose number vs rat Peff values representing the four classes of tested 
compounds 
The biopharmaceutical properties of a drug determine the pharmacokinetic characteristics 
as below: 
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Class I, Do <0.5, Peff (rat) > 5.09×10-5 cm/sec 
The drugs in this category are highly soluble and highly permeable and are ideal candidates 
for oral delivery. These drugs are characterized by the high An, high Dn and low Do, 
showing that they are in solution form throughout the intestine and is available for 
permeation. Therefore the rate of absorption of drugs in this class is controlled only by 
gastric emptying. Examples of this category include antipyrine and propranolol. 
Class II, Do > 1, Peff (rat) > 5.09×10-5 cm/sec 
Class II drugs have high lipophilicity and therefore are highly permeable across the Gl 
membrane, primarily by passive transport. These drugs are characterized by mean 
absorption time less than mean dissolution time, and thus gastric emptying and GI transit 
are important determinants of drug absorption (Varma et al., 2004). These drugs are 
expected to have a dissolution-limited absorption and an IVIVC is expected (Lennernas and 
Abrahamsson, 2005). Low dissolution rate of these molecules limit the concentration at the 
site of absorption thereby leading to less passive diffusion. Therefore formulation plays an 
important role in the rate and extent of intestinal absorption of such drugs. Although there 
are methods to enhance the solubility of class II drugs (Valizadeh et al., 2004, Valizadeh et 
al., 2007), incorporation of polar groups into the chemical backbone, salt generation and 
prodrug approaches are the primary methods for improving deliverability during lead 
optimization.. This class includes drugs such as ketoprofen, naproxen, piroxicam and 
carbamazepine. 
Class III, Do <0.5, Peff (rat) < 4.2×10-5 cm/sec 
The absorption of class III drugs is limited by their intestinal permeability and no IVIVC 
should be expected. These drugs are either having unfavorable physicochemical properties 
leading to less intrinsic permeability and/or are strong substrates to efflux transporters 
and/or gut wall metabolic enzymes (Varma et al., 2004). Therefore the rate and extent of 
intestinal absorption may be controlled by drug molecule properties and physiological 
factors rather than pharmaceutical formulation properties (Yu et al., 2002). They must 
possess optimum lipophilicity in order to permeate the lipophilic epithelial cell membranes 
lining the gastrointestinal tract. Thus for highly polar compounds, administration of less 
polar, more lipophilic prodrugs may improve absorption. Balance between the 
hydrophilicity and lipophilicity should be maintained during incorporation of lipophilic 
groups into the structure. Atenolol, hydrochlorothiazide and ranitidine are examples of 
drugs in this group. 
Class IV, Do > 1, Peff (rat) < 4.2×10-5 cm/sec 
Low and variable absorption for these drugs is anticipated because of the combined 
limitation of solubility and permeability. Formulation may improve the bioavailability of 
these drugs. However they are compromised by their poor intestinal membrane 
permeability. These drugs are more likely susceptible to P-gp efflux and gut metabolism, as 
the concentration of the drug in the enterocytes at any given time will be less to saturate the 
transporter (Varma et al., 2004). Strategies to improve both solubility and permeability 
should be worked out for these molecules, which may not be an easy task. However, 
obtaining this type of quality information will certainly improve drug design and help in 
optimizing candidates with "brick-like” properties. 
Borderline Class, 0.5 <Do <1 or 4.2×10-5 < Peff (rat) < 5.09×10-5 cm/sec 
In this region, bordered by the dashed lines of the four cutoff points, the predictions become 
more uncertain for drugs lying. Cimetidine which is supposed to be in class III, has been 
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classified in this region. All in all, 13 of 15 test drugs (87%) are correctly classified with 
respect to their rat Peff values, however, metoprolol, a drug with high permeability, was 
classified as a low permeability drug in the presented plot (False negative). Furthermore 
there are some more fundamental parameters describing oral drug absorption. These 
parameters include absorption number, dissolution number, absorption time and 
dissolution time (Varma et al., 2004). There is also an extra parameter named absorbable 
dose which was calculated to propose the absorption limiting steps in oral absorption of 
tested drugs. Three dimensionless parameters (Do, An and Dn) which were shown in Table 
3 can be used to qualitative classification of drugs. The four BCS classes of drugs were 
defined as below on the basis of these three parameters. For easy comparison Table 3 was 
set in which the dimensionless parameters for each class of drugs were compared. 
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Compound 
5.9 ± 0.2 250a 1000 a0.0012.5811784.976.5 0.01 3519359Antipyrine 
5.6 ± 2.0 90 a 33 a 0.0112.44302.1 81.1 0.65 109621Propranolol 
6.2 ± 0.6 200 a 0.01 a80.0 2.780.10 71.2 1915.238 Carbamazepine 
20 ± 2.2 400 a 0.01 a160.010.990.08 18.0 2249.7150 Ibuprofen 
9.6 ± 1.8 50 a 0.05 b4.0 4.810.50 41.1 395.8328 Ketoprofen 
11 ± 0.2 500 a 0.01 b200.05.980.10 33.1 1947.381 Naproxen 
7.9 ± 4.0 10 a 0.005 a8.0 3.790.04 52.1 4204.726 Piroxicam 
3.3 ± 1.5 100 a 1000 a0.00041.065917.4185.9 0.03 1448424Metoprolol 
3.3 ± 2.0 80 a 0.01 a32.0 1.030.09 190.6 2025.814 Furosemide 
4.8 ± 0.1 200 a 6 c 0.1331.9462.0 102.0 3.1 15841 Cimetidine 
1.6 ± 0.02 100 a 26.5 a0.0150.005242.6 36326.80.81 196 Atenolol 
2.2 ± 1.0 300 a 1000 a0.0010.418800.8480.6 0.02 560303Ranitidine 
2.0 ± 1.0 50 a 1 a 0.2000.2611.0 747.0 17.9 360 Hydrochlorothiazide
Table 3. Dose, solubility and calculated oral drug absorption parameters for tested 
compounds (Zakeri-Milani et al., 2009b) 
 
Solubility PermeabilityDimensionless  parametersClass
High High An↑*  Dn↑   Do↓ I 
Low High An↑  Dn↓   Do↑ II 
High Low An↓  Dn↑   Do↓ III 
Low Low An↓  Dn↓  Do↑ IV 
*symbols↓ and↑ represent low and high quantity for parameters 
Table 4. Qualitative classification of drugs based on dimensionless parameters 
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Condition Comments Examples 
Absorption 
limiting step 
Tdiss< 50 min 
Peff rat > 4.2×10-5 
Dabs >> Dose 
There is no limitation in drug 
absorption since all three 
parameters are in acceptable 
range. 
Antipyrine, 
Propranolol, 
Cimetidine 
No limited 
Tdiss > 199 min 
Peff rat > 4.2×10-5 
Dabs >> Dose 
Although solubility itself imparts 
to poor dissolution, the 
dissolution here mainly refers to 
particle size. The absolute 
bioavailability increases with 
increasing dose. 
Ketoprofen, 
Piroxicam 
Dissolution 
limited 
Tdiss > 199 min 
Peff rat > 4.2×10-5 
Dabs < Dose 
Solubility-limited absorption 
occurs mainly when a high dose 
saturates part of the gut. The 
absolute bioavailability does not 
increase with increasing dose. 
Ibuprofen, 
Carbamazepine
, 
Naproxen 
Solubility 
limited 
Tdiss< 50 min 
Peff rat < 4.2×10-5 
Dabs >> Dose 
This limiting step is considered 
for highly soluble drugs dosed in 
solutions: assume no 
precipitation occurs. The 
absolute bioavailability increases 
with increasing dose. 
Ranitidine, 
Atenolol, 
Metoprolol, 
Hydrochlorothi
azide 
 
Permeability 
limited 
Tdiss > 199 min 
Peff rat < 4.2×10-5 
Dabs < Dose 
Drug absorption is limited by all 
steps including solubility, 
permeability and dissolution 
Furosemide 
Dissolution-
permeability-
solubility-
limited 
Table 5. Absorption limiting steps and their corresponding conditions 
This classification is in accordance with quantitative classification model which was given in 
the first part of current section, i.e. all compounds lie in the same class as did in quantitative 
classification. For example atenolol with a Do = 0.015 (low), An = 0.005 (low) and Dn = 242 
(high) is classified in class III which is in agreement with above-mentioned QBCS. Again 
metoprolol with An of 1.06 lies in class III as it did before in quantitative model. However 
this is a false negative result, since it was known to have a high permeability belonging to 
class I. Another interesting aspect of using these dimensionless parameters is to determine 
the absorption limiting steps which was summarized as a framework in Table 5. As it was 
mentioned before, the mean small intestinal transit time was found to be 199 minutes with a 
standard deviation of 78 minutes (Yu, 1999, Zakeri-Milani et al., 2009b). This means that as a 
worst case, the small intestinal transit in some individuals may be only 43 minutes (mean 
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small intestinal transit time – 2 × standard deviation). The time of 50 minutes was used as a 
reference time of dissolution to determine if the dissolution is fast enough to permit 
complete dissolution in the small intestine (Yu, 1999). The Peff (rat) was set at 4.2×10-5 cm/sec 
which based on our correlations, corresponds to over 80% of dose absorbed. Table 3 
provides distinguishing conditions under which each limiting case occurs. Considering 
these conditions, antipyrine and propranolol meet the criteria for no-limited absorption. All 
of these three drugs belong to class I. However cimetidine a drug which was false positive 
in our previous quantitative and qualitative classification lies in no-limited class again. On 
the other hand based on dissolution time, permeability and absorbable dose for furosemide, 
a drug of class IV, its absorption would be limited by all three parameters. Therefore it takes 
place in the last class of Table 5. Furthermore drugs with low permeability which have a 
high absorbable dose and low dissolution time such as ranitidine and hydrochlorothiazide 
(class III), are classified in permeability-limited category. Finally the drugs of remaining 
class of BCS (class II) are divided in two groups based on their relative values of 
dimensionless parameters. All of these drugs have high dissolution time (Table 3), but 
regarding the absorbable dose, their absorption could be dissolution or solubility-limited. 
For instance, piroxicam and ketoprofen lie in dissolution-limited class, while naproxen is 
placed in solubility-limited category. According to obtained results and proposed 
classification for drugs, it is concluded that drugs could be categorized correctly based on 
dose number and their Peff values in rat model using SPIP technique. This classification 
enables us to remark defined characteristics for intestinal absorption of all four classes using 
suitable cutoff points for both dose number and rat effective intestinal permeability values. 
Therefore the classification of drugs using their intestinal permeability values in rats can 
help pharmaceutical companies to save a significant amount in development time and 
reduce costs. Moreover it could be as a regulatory tool to substitute in vivo bioequivalence 
(BE) studies by in vitro dissolution tests.  However this work relies on only 13 compounds 
which their Peff values in rat were measured and to confirm the proposed classification the 
larger data set is needed. 
12. Biopharmaceutical classification of drugs using intrinsic dissolution rate 
(IDR) and rat intestinal permeability 
The solubility and dissolution rate of active ingredients are of major importance in 
preformulation studies of pharmaceutical dosage forms (Valizadeh et al., 2007, Valizadeh et 
al., 2004, Barzegar-Jalali et al., 2006, Zakeri-Milani et al., 2009a). The formulation 
characteristics including shelf life, process behavior, and even the bioavailability are affected 
by physicochemical properties of drug molecules (Haleblian and McCrone, 1969). The 
intrinsic dissolution rate (IDR) has been used to characterize solid drugs for many years. For 
example it could be used to understand the relationship between the dissolution rate and 
crystalline form and also to study the effects of surfactants and pH on the solubilization of 
poorly soluble drugs (Amidon et al., 1982, Yu et al., 2004, Zakeri-Milani et al., 2009a).  IDR is 
generally defined as the dissolution rate of a pure drug substance under the condition of 
constant surface area, agitation or stirring speed, pH and ionic strength of the dissolution 
medium. The true intrinsic dissolution rate may be better described as the rate of mass 
transfer from the solid surface to the liquid phase. The apparatus for intrinsic dissolution 
testing was originally developed by John Wood which enables the calculation of the 
dissolution rate per centimeter squared of the intrinsic ingredients of pharmaceutical 
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products (Levy and Gumtow, 1963, Nelson, 1958). It has been suggested that it might be 
feasible to use IDR to classify drugs instead of solubility (Yu et al., 2004). The reason is that, 
just like permeability, IDR is a rate phenomenon instead of an equilibrium phenomenon. 
Therefore it might correlate better with in vivo drug dissolution rate than solubility, 
although for drugs having either extremely high or low dose, discrepancies may exist 
between the solubility and IDR methods  since dose is considered in the classification of 
solubility while intrinsic dissolution does not consider the effect of dose. In the present 
study the intrinsic dissolution rate and rat intestinal permeability (using SPIP technique) 
were measured for drugs with different physicochemical properties. The suitability of IDR-
permeability for biopharmaceutical classification of drugs was evaluated. 
13. Procedure of IDR measurement 
A quantity of 100 mg of each drug was compressed at an average compression force of 7.84 
MPa for 1 minute to make non-disintegrating compacts using die and punch with diameter 
of 6 mm. The surface area of the compacts was 0.2826 cm2. The improved method of wood et 
al was used for disk dissolution studies (Wood et al., 1965). Compacts were placed in a 
molten beeswax-mold in such a way that only one face could be in contact with dissolution 
medium. Dissolution study was conducted using USP II dissolution apparatus using 900mL 
of phosphate buffer (pH=6.8) at temperature of 37°C ± 1°C as the dissolution media with 
paddle rotating at 100 rpm. Samples were collected through 0.45-µm syringe filters over a 
period of 8 hours for low-soluble and 20 minutes for highly soluble drugs. Sampling time 
intervals were 30 min and 2 min respectively. All studies were carried out in triplicate. 
Absorbances were determined in triplicate using a UV-Vis spectrophotometer at the 
maximum absorbance wavelength for each active tested. The cumulative amount dissolved 
per surface unit of the compact was plotted against time for each vessel. The slope of the 
linear region (R2≥ 0.95) was taken as intrinsic dissolution rate. IDR is easily calculated by 
 G = (dw/dt)(1/S) = DCs/h  (25) 
where G is intrinsic dissolution rate (mg/min/cm2); dw is the change in drug dissolved 
(mg); dt is the change in time (minutes); S is the surface area of the compact (cm2); D is 
diffusion coefficient (cm2/sec); Cs is solubility (mg/cm3) and h is stagnant layer thickness 
(cm) (Zakeri-Milani et al., 2009a). 
14. Solubility studies 
Solubilities were determined in at least triplicates by equilibrating excess amount of drugs in 
phosphate buffer solutions (pH=6.8). The samples were kept in thermostated water bath at 
37°C and shaked at a rate of 150 rpm for 24 hours. The absorbances of filtered and suitably 
diluted samples were measured with an UV-VIS spectrophotometer at the maximum 
absorbance wavelength for each active tested. The solubilities were calculated using 
calibration curves determined for each drug (Zakeri-Milani et al., 2009a). Current BCS 
guidance defines an API as “highly soluble” when the highest dose recommended is soluble 
in 250 mL or less of aqueous media over the pH range of 1.2 to 7.5 (Gupta et al., 2006). 
However the pH 6.8 is scientifically justified over pH 7.4 (Gupta et al., 2006). In order to set 
a condition for BCS classification of compounds and since small intestine is the major site for 
drug absorption, where the pH is about 6.8, IDR measurements were conducted in pH 6.8. 
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The presence of sink condition in dissolution medium during the experiment is upholded by 
comparison of the final concentration of drugs and their solubility in dissolution medium. 
Classification of tested drugs based on their intestinal permeability and IDR for human and 
rat is shown in Fig. 9 and Fig. 10 respectively. Drugs are scientifically identified based on 
their solubility and human intestinal permeability. Since human intestinal permeability 
could be predicted with precise using the rat effective permeability values, the same 
classification can be constructed utilizing the solubility and rat intestinal permeability 
values. IDR is a parameter which could be used easily to characterize the pure drug 
substance. The determination of this parameter allows labs to screen experimental drug 
formulations and to understand their behavior under different bio-physical conditions. 
Table 6 shows the obtained solubility and IDR values in the present work for tested drugs. 
 
Drug class 
Wavelength 
(nm) 
Solubility 
(mg/l) 
IDR
(mg 
cm-2 
min-1)This 
work*
This 
work** 
BCSBDDCS
Dissolution 
based 
Compound 
243 683271.656.79I I I I I Antipyrin 
274 779580.834.64I III I I I Metoprolol 
288 71797.1716.596I I I I II Propranolol 
274 71602.6416.192I I I I I Verapamil 
261 2121.80 0.6348II II I I II Ketoprofen 
262 1604.45 0.388II II II II II Naproxen 
285 164.59 0.0355II II II II IV Carbamazepine 
222 1315.41 0.2844II II II II - Ibuprofen 
353 157.64 0.0739II II II II - Piroxicam 
224 16868.143.449III III III III III Atenolol 
219 46276.68 7.2 III III III III - Cimetidine 
228 >1000000 42.18III III III III III Ranitidine 
277 1464.42 0.58 IV IV IV IV IV Furosemide 
* proposed class based on IDR and human intestinal permeability 
 **proposed class based on IDR and rat intestinal permeability 
Table 6. Experimental wavelength, Solubility, intrinsic dissolution rate (IDR), and respective 
class of tested compounds using different approaches 
The IDR results on tested drugs are in agreement with previously reported values (Yu et al., 
2004). In the present study the obtained rat Peff values showed a high correlation (R2=0.93, 
P<0.0001) with human Peff data for passively absorbed compounds confirming the validity 
of our procedure (Zakeri-Milani et al., 2007). It was found that a strong correlation was 
observed between rat permeability data and fraction of oral dose absorbed in human (R2= 
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0.91, P<0.0001). The same correlation for human intestinal permeability data and fraction of 
oral dose absorbed gives a lower correlation coefficient (R2= 0.81, P<0.0001). However 
according to obtained equations, the permeabilities of 0.0000509 and 0.000047 cm/sec in rat 
and human respectively corresponds to Fa=85% which are set as cut-off points for highly 
permeable drugs. On the other hand, IDR correlates with the BCS solubility classification 
with 1-2 mg/min/cm2 as a class boundary. It is seen that antipyrin, ranitidine and 
metoprolol with IDRs of 56.79, 42.18 and 34.64 mg/cm2/min respectively have the higher 
values in comparison to others whereas carbamazepine and piroxicam have the lowest 
intrinsic dissolution rate in the series (IDR=0.035 and 0.07 mg/cm2/min respectively). This 
order is almost the same for solubility of mentioned drugs. However in the case of 
permeability this arrangement is not expected. The reason is that the investigated drugs 
belong to all four biopharmaceutical classes. That means a drug with high IDR value may 
belong to high or low permeability classes. In the present study passively absorbed drugs 
are classified based on their intrinsic dissolution rates and human intestinal permeability 
values (Zakeri-Milani et al., 2009a).. IDR was expected to correlate more closely with in vivo 
dissolution dynamics of drug than solubility. Therefore it could be used to correct 
assignment of a drug to a specific BCS class. This classification is presented in Fig 9 and Fig 
10 (Zakeri-Milani et al., 2009a).  
 
 
Fig. 9. Classification of tested drugs based on their human intestinal permeability and IDR 
Based on this classification, drugs are placed in four explicitly defined categories (I-IV) 
which are made by intersections of dashed lines drawn at the cutoff points for permeability 
and IDR. These classes are characterized as below: 
Class I: Peff,rat > 5× 10-5 (cm/sec)   or Peff,human > 4.7× 10-5 (cm/sec)  ,  IDR > 2 (mg/min/cm2) 
Examples of the compounds of this category include propranolol, metoprolol, verapamil 
and antipyrin which exhibit a high dissolution and absorption. However according to 
intestinal permeability estimates in rat, metoprolol is assigned in class III. 
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Fig. 10. Classification of tested drugs based on their rat intestinal permeability and IDR 
Class II: Peff,rat > 5× 10-5 (cm/sec)   or Peff,human > 4.7× 10-5 (cm/sec),  IDR < 1 (mg/min/cm2) 
Drugs like ketoprofen, naproxen, piroxicam, ibuprofen and carbamazepine are included in 
this category. Class II drugs have a high absorption but a low dissolution therefore 
absorption is limited primarily by drug dissolution in the gastrointestinal tract (Amidon et 
al., 1995). 
Class III: Peff,rat < 5× 10-5 (cm/sec)   or Peff,human < 4.7× 10-5 (cm/sec)  ,  IDR > 2 (mg/min/cm2) 
Class III drugs, have high dissolution and low absorption. In vivo permeability is rate 
limiting step for drug absorption . Examples are atenolol, ranitidine and cimetidine.  
Class IV: Peff,rat < 5× 10-5 (cm/sec)   or Peff,human < 4.7× 10-5 (cm/sec) ,  IDR < 1 (mg/min/cm2) 
 
Furosemide is an example of drugs of this category which exhibit a lot of problems for 
effective oral administration. From the obtained results it is provided that the presented 
classification based on IDR and human intestinal permeability of drugs is in high agreement 
with previously introduced classification and most of the compounds are placed in correct 
categories they belong to (Amidon et al., 1995). Although using the rat intestinal 
permeability values instead of human intestinal permeability, metoprolol was almost 
misclassified, considering non-feasibility of using human in intestinal perfusion studies, 
which is the major difficulty in assigning drugs to BCS classes, it may be suggested that 
determined intestinal permeability of drugs in rats could be used as a criterion for 
biopharmaceutical classification of compounds. On the other hand,  it was proposed that a 
biopharmaceutics drug disposition classification system (BDDCS) based on extent of drug 
metabolism could provide an alternative simple method to assign drugs in class I for a 
waiver of in vivo bioequivalence studies (Takagi et al., 2006, Benet et al., 2008, Wu and 
Benet, 2005). According to this classification highly metabolized drugs exhibit high 
permeability. Therefore a drug is considered to be class I if it is highly soluble and highly 
metabolized. However this definition excludes drugs that have high absorption but are 
excreted unchanged in to bile and urine (Takagi et al., 2006). Comparison of our results with 
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BDDCS classification (≥50% being defined as extensive metabolism) of drugs (Wu and 
Benet, 2005) shows high agreement (92% and 85% using human and rat intestinal 
permeability respectively) in classification of tested compounds (Table 6). Another 
classification system namely dissolution-based classification was developed by 
Papadopoulou et al (Papadopoulou et al., 2008) using mean intestinal transit time (MITT), 
mean dissolution time (MDT) and mean absorption time (MAT). The comparison of this 
classification with our results is also shown in Table 6. However in dissolution-based 
classification propranolol and carbamazepine are classifies as class II and class IV drugs 
respectively which are expected to be assigned in class I and II respectively as was shown in 
other classifications in Table 6. It seems that the presented classification could be used to 
waive in vivo bioavailability and bioequivalence studies for immediate release solid oral 
dosage forms which allows pharmaceutical companies to forego clinical bioequivalence 
studies, if their drug product meets the required specification. However at the time being, 
our attempt is to introduce some thermodynamic parameters as a surrogate for permeability 
measurements. 
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